Moonwalk Biosciences raises $70M for RNAi obesity drug targeting fat tissue

Moonwalk Biosciences raised $70 million to advance an RNA-based obesity drug that reduced fat while preserving muscle in preclinical tests.

A preclinical obesity drug that shrank fat while leaving muscle mass intact has attracted $70 million in new financing for its developer, Moonwalk Biosciences. The funding will be used to push the company's lead candidate, MW101, into first-in-human clinical trials, which are targeted for late 2027. MW101 works through RNA interference (RNAi), a mechanism that silences specific genes. The drug is designed to target adipose tissue — body fat — using small interfering RNA (siRNA) molecules. In preclinical studies, it produced weight loss and fat reduction without the loss of lean muscle mass that can accompany other obesity treatments. Beyond MW101, Moonwalk plans to use the new capital to expand its broader pipeline of siRNA medicines for obesity and cardiometabolic diseases, and to build out its proprietary drug discovery platform. The company is entering a crowded but fast-growing obesity therapeutics field, which has been transformed in recent years by GLP-1 receptor agonists such as semaglutide.

Why it matters

Obesity and related cardiometabolic conditions affect hundreds of millions of people worldwide, and the ability to selectively reduce fat without muscle loss would address a key limitation of current weight-loss therapies. Moonwalk's RNAi approach represents a mechanistically distinct alternative to the dominant GLP-1 drug class.

What's next

First-in-human trials of MW101 are planned for late 2027.

Key facts

• Moonwalk Biosciences raised $70 million in new financing
• Lead candidate MW101 uses RNA interference (siRNA) to target adipose tissue
• Preclinical studies showed weight loss and fat reduction while muscle mass was maintained
• First-in-human trials are targeted for late 2027
• Funding will also support expansion of a broader cardiometabolic disease pipeline and drug discovery platform

Bias & framing notes

Both sources report the same core facts — the $70 million raise, the RNAi mechanism, and the obesity focus — with no meaningful factual disagreement. BioSpace emphasized the clinical timeline and the fat-versus-muscle preclinical finding, while GEN highlighted the broader pipeline and platform-building strategy. Neither source provided critical perspectives or details on the financing structure or investors.

NewsClear — neutral news & congressional tracking · Bill of the Week